Sapient enables small molecule biomarker discovery at unprecedented speed and scale.

What We Enable

Discover more, develop faster, heal quicker.

Learn More

We created Sapient to drive a fundamental shift in today’s costly, slow moving, inefficient drug development process. Sapient applies our biomarker discovery services to provide a deeper understanding of human biology and effectively align biological targets, patients, and drug therapies.

Our Platform

Circulating Biomarker Discovery Engine

Sapient’s three-pronged platform leverages advanced mass spectrometry technologies, computational learning, and a proprietary longitudinal Human Biology Database to enable population-level discovery of small molecule biomarkers, and derive actionable insights to optimize and expedite drug development.

Drug Creation

High-throughput mass spectrometry technologies perform untargeted profiling of >11,000 small molecule biomarkers per biosample, in <1 minute per sample run.
Analytical Technologies
Data science algorithms and machine learning tools are applied to the data to reveal key biomarkers of biological processes, disease progression, and drug response.
Computational Learning
Comprised of data from hundreds of thousands of human biosamples, with more than 10-30 years of follow-up data across patients, this repository can be used to cross-validate identified biomarkers.
Human Biology Database

Together these technologies drive significant speed and scale advantages.

Read Case Studies

Ability to assay


small molecule biomarkers per biosample

Capacity to analyze


of biosamples per day